Bavarian Nordic AS - Company Profile
Powered by 
All the data and insights you need on Bavarian Nordic AS in one report.
$295
- Save hours of research time and resources with
our up-to-date Bavarian Nordic AS Strategy Report
- Understand Bavarian Nordic AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Bavarian Nordic AS (Bavarian Nordic) is a vaccine company that develops, manufactures and commercializes vaccines for the prevention of life-threating diseases. The company develops its products using poxvirus-based technology platforms including modified vaccinia Ankara –Bavarian Nordic (MVA-BN). The company’s marketed products include JYNNEOS for smallpox and monkeypox; Encepur for tick-borne encephalitis; MVABEA for ebola; and Rabipur/RabAvert for rabbies. Its pipeline products are intended for the treatment of smallpox, COVID-19, respiratory syncytial virus, HER2- and brachyury-expressing cancers and Ebola infections. Bavarian Nordic has collaboration with the US government and various institutes, to develop its product candidates for the treatment of cancer and infectious diseases. It has a presence in the US, Denmark, Switzerland and Germany. Bavarian Nordic is headquartered in Hellerup, Denmark.
Headquarters
Denmark
Address
Philip Heymans Alle 3, Hellerup, 2900
Website
www.bavarian-nordic.com
No of Employees
1,379
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BAVA (CPH)
Revenue (2022)
$1.0B
124.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
524.7%
(2022 vs 2021)
Market Cap*
$1.7B
Net Profit Margin (2022)
XYZ
289.4%
(2022 vs 2021)
* As of and is in US$
Bavarian Nordic AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Jynneos/Imavanex- Smallpox and Monkeypox Vaccine | Jynneos |
| Rabipur/Rabavert- Rabies Vaccine | Imvanex |
| Encepur- Tick-Borne Encephalitis Vaccine | Imvamune |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In April, the company introduced JYNNEOS, a Mpox vaccine in the US. |
| 2023 | Acquisitions/Mergers/Takeovers | In May, the company acquired travel health business portfolio from Emergent BioSolutions Inc. |
| 2022 | Contracts/Agreements | In December, the company entered into an agreement with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for the advanced development of MVA-BN WEV. |
Competitor Comparison
| Key Parameters | Bavarian Nordic AS | Moderna Inc | BioNTech SE | Novavax Inc | Icosavax Inc |
|---|---|---|---|---|---|
| Headquarters | Denmark | United States of America | Germany | United States of America | United States of America |
| City | Hellerup | Cambridge | Mainz | Gaithersburg | Seattle |
| State/Province | - | Massachusetts | Nordrhein-Westfalen | Maryland | Washington |
| No. of Employees | 1,379 | 5,600 | 6,133 | 1,543 | 60 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Luc Debruyne | Chairman | Executive Board | 2023 | 60 |
| Paul Chaplin | Chief Executive Officer; President | Senior Management | 2014 | 56 |
| Henrik Juuel | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 58 |
| Russell Thirsk | Chief Operating Officer; Executive Vice President | Senior Management | 2022 | 55 |
| Anu Helena Kerns | Chief People Officer; Executive Vice President | Senior Management | 2020 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward